COST-EFFECTIVENESS ANALYSIS OF CAMRELIZUMAB VS. PLACEBO ADDED TO CHEMOTHERAPY AS FIRST-LINE THERAPY FOR ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINA

Account has been disabled due to a violation of Terms of Service. Contact Moderators

Account has been disabled due to a violation of Terms of Service. Contact Moderators

Blog Article

Report this page